Showing posts with label Public Citizen Health Research Group. Show all posts
Showing posts with label Public Citizen Health Research Group. Show all posts

Sunday, July 5, 2009

Joining the Health Care Debate


My dear friend Susan lives in Canada and complained the other day about how her friend has had to wait three months for a follow-up mammography when a first one came back suspicious. She used that as the example of why a single-payer system creates a terrifyingly rationed health care system. I have recently had a health care crisis, and I, too, having exorbitantly expensive health care paid for by my employer, have had to wait. The myth of rationed health care is part of the propaganda campaign being waged by the insurance industry lobby. We already have to wait for procedures. The difference in America is that if you know the right person, you can move yourself up the list.

Another privilege that remains invisible to most mortals.

We subscribe to the Public Citizen Health Research Group Health Letter.

Its June 2009 issue takes on the silence in the current health care debate on the efficacy of a single-payer system. Essential to the debate is a comparison between a single-payer system and the universal coverage based on multiple payers, meaning that there would be competing insurance companies providing service. Here is an excellent issue-by-issue discussion of the benefits of a single-payer system.

You can keep current with legislative efforts to change our health care system by going here.

Most of the criticism about single-payer is paid criticism coming from the insurance companies that have a lot to lose. Like most American industry, rather than invest in the future, insurance companies during the last twenty years, wasted money buying each other up and paying off massive debt while laying off workers. Back when, doctors were paid, some say extravagantly, but I believe commensurate with their education, but now its insurance executives and the owners of for-profit health care facilities that make the money. My primary health care doctor, a lovely man who spends time with his patients, no longer has the income he once had. He's even moved from being a Republican to a Democrat in the Bush years. Every time I open the New York Times and see another supplement advertising health care services, I get angry. We shouldn't be marketing health care, but promoting good health. There is a difference.

The worst aspect of the multiple payers health care system involves risk pooling. Under a single-payer system, the entire population is part of a single risk pool. People with pre-existing conditions cannot be excluded. However, in the current system, insurance companies attempt to attract lower risk patients, and premiums vary according to risk. Insurance becomes unaffordable for many with health care conditions that then lead to becoming uninsured. The New York Times, this week, finally wrote about the bankruptcy of those with health insurance, because the small print excluded many expensive and needed procedures. Three-quarters of those pushed into bankruptcy over medical bills had insurance at the time of on-set of their disease or condition. It's the limited coverage problem that pervades the private insurance business, and will pervade any health care reform if we do anything less than single-payer.

We need to inform ourselves and fight back against one of the most powerful lobbies in the nation. President Obama is right to take on the issue, now let's make sure he really solves it, and just doesn't do a cosmetic job that doesn't do what it needs to do. With so many Americans aging out of the job market, as the Boomers grow up, and with childhood obesity at crisis levels, we had better prepare for providing health care fairly and equitably across the population.

Thursday, January 1, 2009

Putting a Finger on the Pulse of American Health Care


We subscribe to the Public Citizen Health Research Group monthly newsletter "Health Letter" along with its other monthly edition "Worst Pills, Best Pills." The "Health Letter" examines policy affecting health care. "Worst Pills, Best Pills" deals directly with pharmaceuticals. While my elderly parents were still alive, "Worst Pills, Best Pills" saved their lives. I was able to be a far more assertive advocate with doctors and hospital staffs with the ammunition this newsletter provided. At one point, I learned that my father was taking both Vioxx and Plavix, which was causing internal bleeding that led to severe anemia. His doctor didn't know that the combination could be lethal. I did.

In the December 2008 Health Letter, Public Citizen reviewed some of the worst in health in 2008. The first story affects me. It took 21 months after the completion of the study to reveal that Vytorin, a combination of Zetia and Zocor, used to allegedly treat both genetic as well as environmental causes of higher cholesterol, and which cost 16 times more than the generic of Zocor, was no more effective than Zocor alone in decreasing plaque deposits in the arterial system. When I read about the study in the New York Times, I immediately called my doctor and demanded to be placed on generic Zocor. My monthly costs went from $50 to $25.

The disturbing fact is that the US Supreme Court also held in 2008 in a case Riegel v. Medtronic, that patients injured by medical devices cannot sue manufacturers, because the FDA, whose judgment was highly suspect in the Vytorin instance, is the "first and final arbiter of safety." A similar case involving a drug Rezulin was decided 4-4 by the highest court in Warner-Lambert Co. v. Kent, leaving it unclear whether FDA approval of a pharmaceutical will also confer immunity on the manufacturer of a defective or dangerous drug.

Now awaiting decision is Wyeth v. Levine, argued earlier this fall asking the exact question: whether the Food and Drug Administration's approval of a drug's label precludes individual damage suits based on the claim that the label failed to include sufficient information or adequate warnings.

No matter what the Supreme Court said in Riegel or will say in Wyeth, the Congress can change the authority of the FDA so that private enforcement actions are once again permitted. This is an essential must for the new Democratic Congress. Private enforcement actions keep manufacturers at least a little wary about what they throw into the marketplace. We need to protect ourselves from the same sloppiness and greed that got us into the mire of 2008.